SCHEMBL25219471

SCHEMBL25219471

Cn1c(Cl)nc2cc([N+](=O)[O-])c(Br)cc21

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ MAPT P10636 5/20 0.40
▸ LMNA P02545 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ GALR2 O43603 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ PGK1 P00558 1/20 0.38
▸ PKM P14618 3/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ HPGD P15428 1/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ CYP19A1 P11511 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ TYMS P04818 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30533973 0.85 GAA (0.41) SMN1; SMN2MAPTLMNAKDM4EHTT
SCHEMBL25261573 0.85 GAA (0.41) SMN1; SMN2MAPTLMNAKDM4EHTT
SCHEMBL25219556 0.84 SMN1; SMN2 (0.40) SMN1; SMN2MAPTLMNAKDM4EHTT
SCHEMBL30464363 0.84 SMN1; SMN2 (0.40) SMN1; SMN2MAPTLMNAKDM4EHTT
SCHEMBL30896394 0.83 LMNA (0.46) MAPTLMNAKDM4EHTTNPSR1
SCHEMBL25244517 0.79 PGK1 (0.36) SMN1; SMN2MAPTLMNAKDM4EHTT
SCHEMBL31613168 0.77 KDM4E (0.46) SMN1; SMN2MAPTLMNAKDM4EHTT
SCHEMBL4978556 0.77 ALDH1A1 (0.55) SMN1; SMN2MAPTLMNAKDM4EHTT
SCHEMBL11874680 0.76 ALDH1A1 (0.41) MAPTLMNAKDM4EHTTNPSR1
SCHEMBL3834332 0.74 ALDH1A1 (0.50) SMN1; SMN2MAPTLMNAHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203010-A1 BICYCLIC AMINE CDK12 INHIBITORS INCYTE CORPORATION 2023-06-29 — — US disclosed
US-20230203010-A1 BICYCLIC AMINE CDK12 INHIBITORS INCYTE CORPORATION 2023-06-29 — — US disclosed
WO-2023102184-A1 BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS INCYTE CORPORATION (US) 2023-06-08 — — WO disclosed
WO-2023102184-A1 BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS INCYTE CORPORATION (US) 2023-06-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203010-A1 BICYCLIC AMINE CDK12 INHIBITORS CDK12, CDK1, CDK2 SMN1; SMN2 2951/4885MAPT 1673/4885LMNA 1157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback